AstraZeneca will bring 500 high-tech jobs to the Greater Toronto Area (GTA) with an expansion of its research footprint in Canada. The investment will contribute to AstraZeneca’s Research & Development Hub in Mississauga, which focuses on leading global clinical studies in areas including breast, lung and prostate cancer, COVID-19, and chronic kidney disease. It also includes the creation of a new Alexion, AstraZeneca Rare Disease Development Hub, focused on rare disease research.
